Clinical Oncology
Volume 21, Issue 6 , Pages 448-450 , August 2009

Platinum Sensitivity in a BRCA1 Mutation Carrier with Advanced Breast Cancer

  • K. Rhiem

      Affiliations

    • Centre for Hereditary Breast and Ovarian Cancer Cologne and Centre for Integrated Oncology, University Hospital of Cologne, Cologne, Germany
    • ,
  • B. Wappenschmidt

      Affiliations

    • Centre for Hereditary Breast and Ovarian Cancer Cologne and Centre for Integrated Oncology, University Hospital of Cologne, Cologne, Germany
    • ,
  • K. Bosse

      Affiliations

    • Centre for Hereditary Breast and Ovarian Cancer Cologne and Centre for Integrated Oncology, University Hospital of Cologne, Cologne, Germany
    • ,
  • H. Köppler

      Affiliations

    • Medical Oncology Practice, Koblenz, Germany
    • ,
  • A.N. Tutt

      Affiliations

    • The Breakthrough Breast Cancer Research Unit, King's College London School of Medicine, Guy's Hospital, London, UK
    • ,
  • R.K. Schmutzler

      Affiliations

    • Centre for Hereditary Breast and Ovarian Cancer Cologne and Centre for Integrated Oncology, University Hospital of Cologne, Cologne, Germany
    • Corresponding Author InformationAuthor for correspondence: R. K. Schmutzler, Department of Obstetrics and Gynecology, University Hospital of Cologne, Kerpener Str. 34, 50931 Cologne, Germany. Tel: +49-478-86509; Fax: +49-478-86510.

Received 8 August 2008 ,Revised 5 January 2009 ,Accepted 6 January 2009.

References 

  1. Lakhani SR, van de Vijver MJ, Jaquemier J, et al. The pathology of familial breast cancer: predictive value or immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20:2310–2318
  2. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem. 2007;275:23899–23903
  3. Husain A, He G, Venkatraman ES, Spriggs DR. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res. 1998;58:1120–1123
  4. Fedier A, Steiner RA, Schwarz VA, Lenherr L, Haller Z, Fink D. The effect of loss of BRCA1 on the sensitivity to anticancer agents in p53-deficient cells. Int J Oncol. 2003;22:1169–1173
  5. Meindl A. German Consortium for Hereditary Breast and Ovarian Cancer. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer. 2002;97:472–480
  6. Majdak EJ, Debniak J, Milczek T, et al. Prognostic impact of BRCA1 pathogenic and BRCA1/2 unclassified variant mutations in patients with ovarian carcinoma. Cancer. 2005 Sep 1;104(5):1004–1012
  7. Tassone P, Tagliaferri P, Perricelli A, et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer. 2003;88:1285–1291

PII: S0936-6555(09)00031-4

doi: 10.1016/j.clon.2009.01.006

Clinical Oncology
Volume 21, Issue 6 , Pages 448-450 , August 2009

Article Tools

* Image Usage & Resolution